Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939

Reuters

Yesterday

<a href="https://laohu8.com/S/KNTPF">Kintor Pharmaceutical</a> Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939

Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2566630254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566630254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566630254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566630254","market":"fut","top_or_hot":-1,"title":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KNTPF\">Kintor Pharmaceutical</a> Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 06:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KNTPF\">Kintor Pharmaceutical</a> Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL4TRbDf:1","article_id":"2566630254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566630254","pubTimestamp":1757369567,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939. Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B"},"translate_title":"开拓药业有限公司宣布完成新型酪氨酸酶抑制剂KT-939长期人体安全性试验入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":0.9},"content_text":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939\n    \n\n        Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}